Management Profile

Become a leading global bio pharmaceutical company
for the development of novel drugs


Dr. Shui On LEUNG

Founder, Chairman of our Board, Executive Director, Chief Executive Officer


Dr. Shui On LEUNG, the Founder, was appointed as a Director and the chairman of our Board in April 2001 and subsequently appointed as our chief executive officer in January 2003 and subsequently designated as an executive Director in June 2019. Dr. Leung is primarily responsible for formulating overall strategic directions, overseeing scientific and clinical R&D activities and managing overall operations of our Group. Dr. Leung has nearly 30 years of experience in the field of molecular immunology and therapeutic monoclonal antibodies. Dr. Leung has been a member of the first session of Biotech Advisory Panel of the Stock Exchange since April 2018. Dr. Leung obtained his bachelor’s and master’s degrees in biochemistry from the Chinese University of Hong Kong in December 1984 and October 1986, respectively. He earned his Ph.D. in molecular biology from the University of Oxford in Oxford, England in May 1990. From 2001, Dr. Leung had been an adjunct professor of the Chinese University of Hong Kong and Fudan University, China etc. Dr. Leung also held several positions in a U.S. leading antibody-drug conjugate company.

Mr. Jing QIANG

Executive Director, President


Mr. Qiang has served as the president of the Company since March 2018 and is primarily responsible for strategic planning and investments. Mr. Qiang has over nine years of experience in the field of medicine and healthcare related research and investment, and was qualified as a Chartered Financial Analyst (CFA) by the CFA Institute in September 2011 and as a Financial Risk Manager (FRM) by the Global Association of Risk Professionals in April 2009. Mr. Qiang has been appointed as an executive Director of the Company.

Ms. Wenyi LIU

Non-executive Director


Ms. Wenyi LIU was appointed as a Director in August 2017 and subsequently designated as a non-executive Director in June 2019. Ms. Liu is primarily responsible for providing overall guidance on business and strategic development of our Group. Ms. Liu received her bachelor’s degree in economics from the University of Southampton in Southampton, England in June 2009 and master’s degree in economics from the University of Warwick in Coventry, England in November 2010. Ms. Liu is currently pursuing her Ph.D in healthcare management in a cohort-based program in collaboration between Johns Hopkins Bloomberg School of Public Health and the Institute for Hospital Management of Tsinghua University (清華大學). Ms. Liu obtained the securities qualification certificate issued by the Securities Association of China in November 2011. Ms. Liu has years of experience in investment and operational management in the pharmaceutical industry.

Dr. Haigang CHEN

Non-executive Director


Dr. Haigang CHEN was appointed as a Director in August 2017 and subsequently designated as a non-executive Director in June 2019. Dr. Chen is primarily responsible for providing overall guidance on business and strategic development of our Group. Dr. Chen has nearly 10 years of investment experience in the pharmaceutical industry. Dr. Chen earned his Medical Doctor degree in clinical medicine from Peking Union Medical College (北京協和醫學院) in July 2009. He obtained the securities qualification certificate issued by the Securities Association of China in June 2015.

Mr. Huiyuan MA

Non-executive Director


Mr. Huiyuan MA (馬慧淵), was appointed as a Director in April 2019 and subsequently designated as a non-executive Director in June 2019. Mr. Ma is primarily responsible for providing overall guidance on business and strategic development of our Group. Mr. Ma has more than 20 years of experience in investment. Mr. Ma obtained his bachelor’s degree in flight vehicle engineering from Nanjing University of Science and Technology, China (南京理工大學) (formerly known as East China Institute of Technology (華東工學院)) in July 1986.

Mr. Senlin LIU

Non-executive Director


Mr. Senlin LIU was appointed as a Director in February 2019 and subsequently designated as a non-executive Director in June 2019. Mr. Liu is primarily responsible for providing overall guidance on business and strategic development of our Group. Mr. Liu has over 10 years of experience in corporate finance and investment. Mr. Liu obtained a bachelor’s degree in biomedical engineering and a master’s degree in management science and engineering from Tsinghua University, China in July 2006 and July 2008, respectively.

Mr. Xun DONG

Non-executive Director


Mr. Xun DONG (董汛) has over 20 years of experience in the pharmaceutical industry. Between 1996 and 2004, Mr. Dong worked for Yunnan Baiyao Group Co., Ltd (雲南白藥集團股份有限公司) (“Baiyao Group”). The shares of Baiyao Group are listed on the Shenzhen Stock Exchange (stock code: 000538), and it is one of the 10 Key Large Enterprises in Yunnan Province (雲南省十戶重點大型企業), one of Top 100 Enterprises in Yunnan Province (雲南省百強企業) and one of the first national innovative enterprise. Baiyao Group operates through four segments, namely pharmaceuticals, health products, Chinese medicine resources and pharmaceutical logistics, and is principally engaged in chemical raw material, chemico-pharmaceutical preparations, proprietary Chinese medicines, Chinese medicinal material and biologic products. During the said employment, he rose through the ranks and held the positions of assistant general manager before his departure from Baiyao Group to further his education. He re-joined Baiyao Group in 2006 as a vice president of sales of the native medicine division, and has held various positions since then. Since 2018, Mr. Dong has been holding the positions of director of Yunnan institute of medicine, director of the office of the strategic committee of Baiyao Group and general manager of the innovative research and development centre of Baiyao Group.

Mr. Dylan Carlo TINKER

Independent non-executive Director


Mr. Dylan Carlo TINKER, has been appointed as an independent non-executive Director in October 2019 with effect from October 31, 2019. Mr. Tinker is primarily responsible for supervising and providing independent judgment to our Board. Mr. Tinker has over 25 years of experience in investment banking and capital raising transactions in the field of telecommunications, media, technology (“TMT”) in Asia and has held senior positions in equity research, corporate finance and fund management. Mr. Tinker obtained a B.A. from American University, School of International Service in 1991, with a joint degree in Economics and International Relations. Mr. Tinker attended graduate school at the Paul H. Nitze School of Advanced International Studies (SAIS) of Johns Hopkins University in Washington, D.C., the United States from 1991 to 1993.

Mr. Michael James Connolly HOGAN

Independent non-executive Director


Mr. Michael James Connolly HOGAN (何灝勤), has been appointed as an independent non-executive Director in October 2019 with effect from October 31, 2019. Mr. Hogan is primarily responsible for providing independent judgment to our Board and ensuring a high standard of overall governance. Mr. Hogan has over 30 years of experience in international banking with a particular bias towards wholesale banking, corporate banking, credit and lending, transaction banking, and debt capital markets. Mr. Hogan obtained a bachelor of commerce degree from National University of Ireland in 1987.

Mr. Ping Cho Terence HON

Independent non-executive Director


Mr. Ping Cho Terence HON (韓炳祖), has been appointed as an independent non-executive Director in October 2019 with effect from October 31, 2019. Mr. Hon is primarily responsible for supervising and providing independent judgment to our Board. Mr. Hon has over 34 years of experience in accounting, treasury and financial management. Mr. Hon is a fellow member of the Association of Chartered Certified Accountants, a member of the Hong Kong Institute of Certified Public Accountants and a member of the Institute of Chartered Accountants in England and Wales. He obtained a master’s degree in business administration (financial services) from The Hong Kong Polytechnic University in November 2004.

Mr. George William Hunter CAUTHERLEY

Independent non-executive Director


Mr. George William Hunter CAUTHERLEY has 55 years of experience of distributing a wide range of medical products and pharmaceuticals in Hong Kong, China and South East Asian countries and for the past 40 years through companies of which he has been CEO and substantive shareholder. For almost 20 years his principal business groups have also been involved in manufacturing medical devices and pharmaceuticals in China. In addition to his core business interests, Mr. Cautherley has been an investor in a number of biotechnology start-up/early stage enterprises in Europe and Hong Kong and has served on the boards of several of these companies. Mr. Cautherley was awarded an Honorary Doctorate of Business Administration by Edinburgh Napier University, United Kingdom and the holder of the award of Office of the British Empire (OBE) conferred Queen Elizabeth II of the United Kingdom.